TiGenix NV (NYSE Euronext: TIG) is a leading European cell therapy company with an advanced clinical stage pipeline of adult stem cell programmes, and a commercialised product.

The stem cell programmes are based on a validated platform of allogeneic expanded adipose-derived stem cells (eASCs) targeting autoimmune and inflammatory diseases. Built on solid pre-clinical and CMC packages, they are being developed in close consultation with the European Medicines Agency.  CX601 is in Phase III to treat complex perianal fistulas in patients with Crohn’s disease. Cx611 has successfully concluded a Phase IIa trial in rheumatoid arthritis, and is now in development for early rheumatoid arthritis and for severe sepsis.

The company’s commercialised product, ChondroCelect®, for cartilage repair in the knee, was the first approved cell-based product in Europe, and is marketed and distributed by Swedish Orphan Biovitrum AB (‘Sobi’, NASDAQ OMX Stockholm: SOBI) and Finnish Red Cross Blood Service (FRCBS). TiGenix is based in Leuven, Belgium, and has operations in Madrid , Spain.



Pipeline Update


Latest News

30 July 2015 - TiGenix expands pipeline and enters the cardiology field with clinical-stage company acquisition (EN - NL - FR)

3 July 2015 - Notice in relation to the convertible bonds due 2018 (EN - NL - FR)

11 June 2015 - TiGenix starts Cx601 Marketing Authorisation Application process (EN - NL - FR)

28 May 2015 - Safety and tolerability of Cx611 confirmed in Phase I sepsis challenge trial (EN - NL - FR)

13 May 2015 - Convening notice to the extraordinary shareholders' meeting to be held on 2 June 2015 (EN - NL)


Company presentation slide deck

2015 - Corporate Presentation

Management presentations

2014 full year results webcast recording, March 2015

Tigenix at Alliance for Regenerative Medicine Conference, March 2015

TiGenix on Kanaal Z television, November 2014

Company factsheet

Company factsheet